In order to reveal the hotspots and trends of biological water treatment from the perspectives of scientific and technological innovation, both of the bibliometric review and patents analysis were performed in this st...In order to reveal the hotspots and trends of biological water treatment from the perspectives of scientific and technological innovation, both of the bibliometric review and patents analysis were performed in this study. The Web of Science Core Collection database and Derwent Innovation Index database recorded 30023 SCI papers and 50326 patents, respectively were analyzed via information visualization technology. The results showed that China ranked the first in both papers and patents, while the United States and Japan had advantages in papers and patents, respectively. It was concluded through literature metrology analysis that microbial population characteristics, biodegradation mechanism,toxicity analysis, nitrogen and phosphorus removal and biological treatment of micropolluted wastewater were the research hotspots of SCI papers. Activated sludge process and anaerobic-aerobic combined process were the two mainstream technologies on the basis of patent technology classification analysis. Technology evolution path of biological water treatment was also elucidated in three stages based on the citation network analysis. Furthermore, the future directions including research on the law of interaction and regulation of biological phases and pollutants and the technology innovations towards the targeted biotransformation or selective biodegradation of pollutants and resource reuse of wastewater were prospected.展开更多
AIM:To evaluate the effectiveness of the biological disease-modifying antirheumatic drugs(b DMARD) in the treatment of rheumatoid arthritis through a systematic review of observational studies.METHODS:The studies were...AIM:To evaluate the effectiveness of the biological disease-modifying antirheumatic drugs(b DMARD) in the treatment of rheumatoid arthritis through a systematic review of observational studies.METHODS:The studies were searched in the Pub Med,EMBASE,Cochrane Controlled Trials Register and LILACS databases(until August 2014),in the grey literature and conducted a manual search.The assessed criteria of effectiveness included the EULAR,the disease activity score(DAS),the Clinical Disease Activity Index,the Simplified Disease Activity Index,the American College of Rheumatology and the Health Assessment Questionnaire.The meta-analysis was performed with Review Manager 5.2 software using a random effects model.A total of 35 studies were included in this review.RESULTS:The participants anti-tumor necrosis factor inhibitors(TNF) nave,who used adalimumab(P = 0.0002) and etanercept(P = 0.0006) exhibited greater good EULAR response compared to the participants who used infliximab.No difference was detected between adalimumab and etanercept(P = 0.05).The participants who used etanercept exhibited greater remission according to DAS28 compared to the participants who used infliximab(P = 0.01).No differences were detected between adalimumab and infliximab(P = 0.12) or etanercept(P = 0.79).Better results were obtained with b DMARD associated with methotrexate than with b DMARD alone.The good EULAR response and DAS 28 was better for combination with methotrexate than b DMARD monotherapy(P = 0.03 e P < 0.00001).In cases of therapeutic failure,the participants who used rituximab exhibited greater DAS28 reduction compared to those who used anti-TNF agents(P = 0.0002).The participants who used etanercept achieved greater good EULAR response compared to those who did not use that drug(P = 0.007).Studies that assessed reduction of the CDAI score indicated the superiority of abatacept over rituximab(12.4 vs +1.7) and anti-TNF agents(7.6 vs 8.3).The present systematic review with meta-analysis found that relative to anti-TNF treatmentnave patients,adalimumab and etanercept were more effective when combined with methotrexate than when used alone.Furthermore,in case of therapeutic failure with anti-TNF agents;rituximab and abatacept(non anti-TNF) and etanercept(as second anti-TNF) were more effective.However,more studies of effectiveness were found for the rituximab.CONCLUSION:The best treatment for treatment-nave patients is adalimumab or etanercept combined with methotrexate.For anti-TNF therapeutic failure,the best choice is rituximab,abatacept or etanercept.展开更多
目的:采用Meta分析比较A型肉毒毒素联合类固醇激素与单独类固醇激素治疗病理性瘢痕的疗效及安全性。方法:计算机检索截止2021年3月的Pubmed、EMbase、Cochrane Central Register of controlled Trail、中国知网、万方、维普以及中国生...目的:采用Meta分析比较A型肉毒毒素联合类固醇激素与单独类固醇激素治疗病理性瘢痕的疗效及安全性。方法:计算机检索截止2021年3月的Pubmed、EMbase、Cochrane Central Register of controlled Trail、中国知网、万方、维普以及中国生物医学文献数据库中公开发表的关于A型肉毒毒素联合类固醇激素与单独类固醇激素治疗病理性瘢痕的临床对照实验。由2名研究员根据纳入及排除标准独立筛选文献、提取资料及质量评价。使用RevMan 5.3和Stata 14.0统计软件,对结局指标进行Meta分析。结果:共纳入11项研究,包括8项随机对照试验,3项病例-队列研究,试验组采用A型肉毒毒素联合类固醇激素局灶内注射,对照组采用类固醇激素局灶内注射,纳入文献总体质量较高。Meta分析结果表明,试验组在目测类比评分[WMD=-2.26,95%CI(-3.07,-1.46),P<0.00001]、瘢痕厚度[WMD=-0.94,95%CI(-1.82,-0.06),P=0.04]、满意度评分[WMD=1.51,95%CI(1.21,1.81),P<0.00001]、有效率[RR=1.30,95%CI(1.17,1.43),P<0.00001]、复发率[RR=0.23,95%CI(0.11,0.49),P=0.0002]、不良反应发生率[RR=0.65,95%CI(0.42,0.99),P=0.04]等指标均优于对照组,而治疗后两组间瘢痕长度无显著性差异[SMD=-4.30,95%CI(-11.56,2.96),P=0.25]。结论:A型肉毒毒素联合类固醇激素治疗病理性瘢痕的疗效及安全性均优于单独使用类固醇激素。展开更多
基金supported by the National Natural Science Foundation of China (No. 51878336)the Outstanding Youth Foundation of Jiangsu Province of China (No. BK20200063)。
文摘In order to reveal the hotspots and trends of biological water treatment from the perspectives of scientific and technological innovation, both of the bibliometric review and patents analysis were performed in this study. The Web of Science Core Collection database and Derwent Innovation Index database recorded 30023 SCI papers and 50326 patents, respectively were analyzed via information visualization technology. The results showed that China ranked the first in both papers and patents, while the United States and Japan had advantages in papers and patents, respectively. It was concluded through literature metrology analysis that microbial population characteristics, biodegradation mechanism,toxicity analysis, nitrogen and phosphorus removal and biological treatment of micropolluted wastewater were the research hotspots of SCI papers. Activated sludge process and anaerobic-aerobic combined process were the two mainstream technologies on the basis of patent technology classification analysis. Technology evolution path of biological water treatment was also elucidated in three stages based on the citation network analysis. Furthermore, the future directions including research on the law of interaction and regulation of biological phases and pollutants and the technology innovations towards the targeted biotransformation or selective biodegradation of pollutants and resource reuse of wastewater were prospected.
基金Supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico,Brazil
文摘AIM:To evaluate the effectiveness of the biological disease-modifying antirheumatic drugs(b DMARD) in the treatment of rheumatoid arthritis through a systematic review of observational studies.METHODS:The studies were searched in the Pub Med,EMBASE,Cochrane Controlled Trials Register and LILACS databases(until August 2014),in the grey literature and conducted a manual search.The assessed criteria of effectiveness included the EULAR,the disease activity score(DAS),the Clinical Disease Activity Index,the Simplified Disease Activity Index,the American College of Rheumatology and the Health Assessment Questionnaire.The meta-analysis was performed with Review Manager 5.2 software using a random effects model.A total of 35 studies were included in this review.RESULTS:The participants anti-tumor necrosis factor inhibitors(TNF) nave,who used adalimumab(P = 0.0002) and etanercept(P = 0.0006) exhibited greater good EULAR response compared to the participants who used infliximab.No difference was detected between adalimumab and etanercept(P = 0.05).The participants who used etanercept exhibited greater remission according to DAS28 compared to the participants who used infliximab(P = 0.01).No differences were detected between adalimumab and infliximab(P = 0.12) or etanercept(P = 0.79).Better results were obtained with b DMARD associated with methotrexate than with b DMARD alone.The good EULAR response and DAS 28 was better for combination with methotrexate than b DMARD monotherapy(P = 0.03 e P < 0.00001).In cases of therapeutic failure,the participants who used rituximab exhibited greater DAS28 reduction compared to those who used anti-TNF agents(P = 0.0002).The participants who used etanercept achieved greater good EULAR response compared to those who did not use that drug(P = 0.007).Studies that assessed reduction of the CDAI score indicated the superiority of abatacept over rituximab(12.4 vs +1.7) and anti-TNF agents(7.6 vs 8.3).The present systematic review with meta-analysis found that relative to anti-TNF treatmentnave patients,adalimumab and etanercept were more effective when combined with methotrexate than when used alone.Furthermore,in case of therapeutic failure with anti-TNF agents;rituximab and abatacept(non anti-TNF) and etanercept(as second anti-TNF) were more effective.However,more studies of effectiveness were found for the rituximab.CONCLUSION:The best treatment for treatment-nave patients is adalimumab or etanercept combined with methotrexate.For anti-TNF therapeutic failure,the best choice is rituximab,abatacept or etanercept.
文摘目的:采用Meta分析比较A型肉毒毒素联合类固醇激素与单独类固醇激素治疗病理性瘢痕的疗效及安全性。方法:计算机检索截止2021年3月的Pubmed、EMbase、Cochrane Central Register of controlled Trail、中国知网、万方、维普以及中国生物医学文献数据库中公开发表的关于A型肉毒毒素联合类固醇激素与单独类固醇激素治疗病理性瘢痕的临床对照实验。由2名研究员根据纳入及排除标准独立筛选文献、提取资料及质量评价。使用RevMan 5.3和Stata 14.0统计软件,对结局指标进行Meta分析。结果:共纳入11项研究,包括8项随机对照试验,3项病例-队列研究,试验组采用A型肉毒毒素联合类固醇激素局灶内注射,对照组采用类固醇激素局灶内注射,纳入文献总体质量较高。Meta分析结果表明,试验组在目测类比评分[WMD=-2.26,95%CI(-3.07,-1.46),P<0.00001]、瘢痕厚度[WMD=-0.94,95%CI(-1.82,-0.06),P=0.04]、满意度评分[WMD=1.51,95%CI(1.21,1.81),P<0.00001]、有效率[RR=1.30,95%CI(1.17,1.43),P<0.00001]、复发率[RR=0.23,95%CI(0.11,0.49),P=0.0002]、不良反应发生率[RR=0.65,95%CI(0.42,0.99),P=0.04]等指标均优于对照组,而治疗后两组间瘢痕长度无显著性差异[SMD=-4.30,95%CI(-11.56,2.96),P=0.25]。结论:A型肉毒毒素联合类固醇激素治疗病理性瘢痕的疗效及安全性均优于单独使用类固醇激素。
